Notice Special Interest NOSI): Dissemination Implementation Science Cancer Prevention Control Low Resource Environments Notice Number: NOT-CA-20-025 Key Dates Release Date: February 10, 2020 First Available Due Date: June 5, 2020 Expiration Date: 8, 2022 Related Announcements PAR-19-274 Dissemination Implementation Research Health R01 Clinical Trial Optional) PAR-19-275 Dissemination Implementation Research Health R21 Clinical Trial Optional) PAR-19-276 Dissemination Implementation Research Health R03 Clinical Trial Allowed) Issued NATIONAL CANCER INSTITUTE NCI) Purpose purpose this Notice

Notice Special Interest NOSI): Defining Mechanisms Disease Recurrence Dental, Oral, Craniofacial Tissues Notice Number: NOT-DE-20-001 Key Dates Release Date: February 18, 2020 First Available Due Date: June 05, 2020 Expiration Date: 08, 2022 Related Announcements PAR-19-172 Achieving Tissue Robustness Through Harnessing Immune System Plasticity R01 Clinical Trial Allowed) PAR-19-173 Achieving Tissue Robustness Through Harnessing Immune System Plasticity R21 Clinical Trial Allowed) Issued National Institute Dental Craniofacial Research NIDCR) Purpose NIDCR announces interest encouraging stud

Notice Special Interest NOSI): HIV-HCV-Substance Disorder Syndemic: Therapeutic Approaches Notice Number: NOT-DA-20-032 Key Dates Release Date: February 21, 2020 First Available Due Date: June 05, 2020 Expiration Date: September 08, 2023 Related Announcements PA-19-055, Research Project Grant Parent R01 Clinical Trial Required) PA-19-056, NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-091, NIH Research Project Grant Parent R01 Basic Experimental Studies Humans Required) Issued National Institute Drug Abuse NIDA) Purpose purpose this Notice to communicate National Instit

This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language.

This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

Notice Special Interest NOSI): Exploring Roles Biomolecular Condensates BMCs) Substance Disorder and/or HIV-related processes Notice Number: NOT-DA-20-018 Key Dates Release Date: March 25, 2020 First Available Due Date: June 05, 2020 Expiration Date: September 08, 2023 Related Announcements PA-19-056: NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-091: NIH Research Project Grant Parent R01 Basic Experimental Studies Humans Required) PA-19-052: NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-053: NIH Exploratory/Developmental Research Grant Prog

The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

Notice Special Interest NOSI): Strengthening HIV Prevention Continuum Notice Number: NOT-MH-20-019 Key Dates Release Date: March 27, 2020 First Available Due Date: 07, 2020 Expiration Date: 08, 2023 Related Announcements PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141, Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Cli

This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies.